Medacta Group (MOVE) Aktienübersicht
Medacta Group SA entwickelt, produziert und vertreibt orthopädische und neurochirurgische Medizinprodukte in Lateinamerika, Nordamerika, im asiatisch-pazifischen Raum sowie im Nahen Osten und Afrika. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 6/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für MOVE festgestellt.
MOVE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medacta Group SA Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | CHF 134.20 |
| 52-Wochen-Hoch | CHF 177.20 |
| 52-Wochen-Tief | CHF 128.00 |
| Beta | 0.99 |
| 1 Monat Veränderung | -3.03% |
| 3 Monate Veränderung | -17.36% |
| 1 Jahr Veränderung | 0% |
| 3 Jahre Veränderung | 14.31% |
| 5 Jahre Veränderung | 11.09% |
| Veränderung seit IPO | 39.65% |
Aktuelle Nachrichten und Updates
Analyseartikel • Jun 07
What Is Medacta Group SA's (VTX:MOVE) Share Price Doing?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw significant share price movement during...
Narrativ-Update • Jun 05
MOVE: Earnings Outlook And Dividend Will Support Future Upside Potential
Analysts have nudged their price target on Medacta Group slightly lower to CHF 179.08 from CHF 179.46, reflecting updated fair value assumptions and a modestly lower future P/E multiple, while keeping revenue growth and profit margin expectations essentially unchanged. What's in the News Medacta has been selected to join an international research project focused on recreating dinosaurs from preserved DNA, working alongside Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural Science Museum London (source: company client announcement).Narrativ-Update • Apr 25
MOVE: Earnings Outlook And Dividend Will Drive Future Upside Potential
Analysts have nudged their price target for Medacta Group slightly lower to CHF 179 from about CHF 181. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that are broadly consistent with previous expectations.Narrativ-Update • Apr 11
MOVE: Earnings Outlook And Dividend Will Drive Further Upside Potential
Analysts have nudged their price target for Medacta Group slightly higher to CHF181.43 from CHF180.07, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Medacta has joined an international research project focused on recreating dinosaurs from preserved DNA, working with partners including Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural History Museum in London.Recent updates
Analyseartikel • Jun 07
What Is Medacta Group SA's (VTX:MOVE) Share Price Doing?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw significant share price movement during...Narrativ-Update • Jun 05
MOVE: Earnings Outlook And Dividend Will Support Future Upside Potential
Analysts have nudged their price target on Medacta Group slightly lower to CHF 179.08 from CHF 179.46, reflecting updated fair value assumptions and a modestly lower future P/E multiple, while keeping revenue growth and profit margin expectations essentially unchanged. What's in the News Medacta has been selected to join an international research project focused on recreating dinosaurs from preserved DNA, working alongside Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural Science Museum London (source: company client announcement).Narrativ-Update • Apr 25
MOVE: Earnings Outlook And Dividend Will Drive Future Upside Potential
Analysts have nudged their price target for Medacta Group slightly lower to CHF 179 from about CHF 181. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that are broadly consistent with previous expectations.Narrativ-Update • Apr 11
MOVE: Earnings Outlook And Dividend Will Drive Further Upside Potential
Analysts have nudged their price target for Medacta Group slightly higher to CHF181.43 from CHF180.07, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Medacta has joined an international research project focused on recreating dinosaurs from preserved DNA, working with partners including Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural History Museum in London.Narrativ-Update • Mar 28
MOVE: Earnings Outlook And Dividend Will Support Further Upside Potential
Analysts have raised their price target on Medacta Group to CHF 180.07 from CHF 177.36, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News Company issued earnings guidance for 2026, targeting revenue growth in a range of 10% to 14% in constant currency (Key Developments).Narrativ-Update • Mar 12
MOVE: Slightly Higher Return Hurdle Will Still Support Future Upside
The analyst price target for Medacta Group has been adjusted slightly lower to reflect a revised fair value of about CHF 177.36, with analysts pointing to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: CHF 177.36, slightly lower than the prior estimate of CHF 178.87.Narrativ-Update • Feb 26
MOVE: Slightly Higher Return Hurdle And Lower P/E Will Still Support Upside
Analysts have maintained their CHF 178.87 price target for Medacta Group, with the slight adjustment in discount rate and lower assumed future P/E multiple reflecting a more cautious stance on valuation assumptions while keeping the overall target level unchanged. Valuation Changes Fair Value: CHF 178.87 remains unchanged, indicating no adjustment to the overall fair value estimate.Narrativ-Update • Feb 10
MOVE: Higher Growth Assumptions And Richer P/E Will Support Gradual Upside
Analysts have nudged their price target for Medacta Group slightly higher, to €178.87 from €178.20, reflecting updated views on discount rates, revenue growth, profit margins, and the future P/E multiple. Valuation Changes Fair Value: updated slightly higher from €178.20 to €178.87.Narrativ-Update • Jan 25
MOVE: Modest Assumption Tweaks And Firm Margins Will Underpin Gradual Performance
Analysts have raised their price target on Medacta Group to approximately CHF 178 from about CHF 167, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and a future P/E of roughly 35x in their updated models. Valuation Changes Fair Value: Updated model fair value moves from about CHF 166.69 to roughly CHF 178.20 per share.Analyseartikel • Jan 21
Subdued Growth No Barrier To Medacta Group SA's (VTX:MOVE) Price
With a price-to-earnings (or "P/E") ratio of 38.5x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...Narrativ-Update • Jan 08
MOVE: Steady Margins And Refined Assumptions Will Support Gradual Performance
Analysts have nudged their price target on Medacta Group slightly higher to reflect a modestly lower discount rate and a small refinement in assumed future P/E. This suggests a fine tuning of their valuation rather than a major shift in view.Analyseartikel • Dec 30
Is It Time To Consider Buying Medacta Group SA (VTX:MOVE)?
While Medacta Group SA ( VTX:MOVE ) might not have the largest market cap around , it saw a double-digit share price...Narrativ-Update • Dec 25
MOVE: Steady Margins And Fair Pricing Will Support Gradual Performance
Narrative Update on Medacta Group Analysts have modestly raised their price target on Medacta Group, citing a slightly higher long term discount rate and marginally richer future earnings multiple expectations that together point to a fair value of approximately CHF 166.70 per share. Valuation Changes Fair Value Estimate, unchanged at approximately CHF 166.70 per share, indicating no revision to the central valuation outcome.Narrativ-Update • Dec 11
MOVE: Lower Risk And Steady Margins Will Support Gradual Performance Outlook
Analysts have modestly raised their price target on Medacta Group to approximately CHF 166.70 from around CHF 164.40, reflecting slightly lower perceived risk, a marginally stronger long term profit margin outlook, and a small upward revision to anticipated future valuation multiples. Valuation Changes Fair Value has risen slightly from approximately CHF 164.40 to about CHF 166.70, implying a modest increase in the assessed intrinsic value.Narrativ-Update • Nov 26
MOVE: Stable Earnings Guidance And Margins Will Support Measured Performance Outlook
Analysts have maintained their price target for Medacta Group at CHF 164.40. They cite steady profit margin expectations and a stable outlook for revenue growth, despite minor adjustments to the discount rate.Narrativ-Update • Nov 10
MOVE: Revenue Will Hold Steady as Earnings Guidance Signals Further Upside
Narrative Update: Medacta Group Price Target Adjustment Analysts have slightly lowered their fair value estimate for Medacta Group from CHF164.46 to CHF164.40, citing minor model updates that reflect changes in discount rate assumptions. What's in the News Medacta Group SA confirmed its earnings guidance for 2025, targeting revenue growth of 16% to 18% in constant currency, subject to unforeseen events (Company Guidance).Analyseartikel • Nov 08
Medacta Group (VTX:MOVE) Is Looking To Continue Growing Its Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Narrativ-Update • Oct 27
Earnings Guidance And Updated Outlook Will Drive Expansion Across New Markets
Analysts have raised their price target for Medacta Group from CHF156.91 to CHF164.46, citing modest adjustments to growth and margin expectations as reflected in updated forecasts. What's in the News Medacta Group SA confirmed its earnings guidance for 2025, targeting revenue growth in the range of 16% to 18% in constant currency, subject to unforeseen events (Key Developments).Analyseartikel • Oct 21
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Oct 01
Investor Optimism Abounds Medacta Group SA (VTX:MOVE) But Growth Is Lacking
When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...Analyseartikel • Sep 13
Medacta Group's (VTX:MOVE) Solid Profits Have Weak Fundamentals
Medacta Group SA ( VTX:MOVE ) just reported some strong earnings, and the market reacted accordingly with a healthy...Analyseartikel • Sep 12
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?
While Medacta Group SA ( VTX:MOVE ) might not have the largest market cap around , it saw a decent share price growth...Analyseartikel • Aug 29
Estimating The Fair Value Of Medacta Group SA (VTX:MOVE)
Key Insights Medacta Group's estimated fair value is CHF129 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Aug 01
Medacta Group (VTX:MOVE) Has Some Way To Go To Become A Multi-Bagger
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analyseartikel • Jun 24
Do Medacta Group's (VTX:MOVE) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • May 24
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw a significant share price rise of 23...Analyseartikel • May 10
Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher
Medacta Group SA ( VTX:MOVE ) shareholders would be excited to see that the share price has had a great month, posting...Analyseartikel • May 01
Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why
Key Insights Medacta Group's Annual General Meeting to take place on 7th of May Total pay for CEO Francesco Siccardi...Analyseartikel • Apr 24
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Apr 10
Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Analyseartikel • Mar 28
Medacta Group SA (VTX:MOVE) Yearly Results: Here's What Analysts Are Forecasting For This Year
The full-year results for Medacta Group SA ( VTX:MOVE ) were released last week, making it a good time to revisit its...Analyseartikel • Feb 13
Medacta Group SA (VTX:MOVE) Looks Just Right With A 25% Price Jump
Medacta Group SA ( VTX:MOVE ) shareholders would be excited to see that the share price has had a great month, posting...
Neues Narrativ • Feb 09
New Products Like GMK SpheriKA And NextAR Will Strengthen Future Prospects In The Spine Segment
Medacta's innovation in product launches and medical education expansion drives revenue growth, with a strong focus on the Spine segment and ASCs.Analyseartikel • Jan 06
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Analyseartikel • Nov 22
The Price Is Right For Medacta Group SA (VTX:MOVE)
When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...Analyseartikel • Oct 14
Is Medacta Group (VTX:MOVE) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Sep 06
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Key Insights Medacta Group's estimated fair value is CHF95.33 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Aug 21
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
While Medacta Group SA ( VTX:MOVE ) might not have the largest market cap around , it saw a double-digit share price...Analyseartikel • Aug 06
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Analyseartikel • Jun 20
Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
With a price-to-earnings (or "P/E") ratio of 54x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...Analyseartikel • May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Key Insights Medacta Group will host its Annual General Meeting on 7th of May Total pay for CEO Francesco Siccardi...Analyseartikel • Apr 17
Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Mar 29
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), might not be a large cap stock, but it received a lot of attention from a substantial...Analyseartikel • Feb 22
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Feb 07
Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Analyseartikel • Dec 18
Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
With a price-to-earnings (or "P/E") ratio of 51.3x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...Analyseartikel • Dec 04
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Key Insights The projected fair value for Medacta Group is CHF109 based on 2 Stage Free Cash Flow to Equity Medacta...Analyseartikel • Nov 15
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...Analyseartikel • Oct 30
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...Analyseartikel • Oct 17
If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Sep 29
Is Medacta Group (VTX:MOVE) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Aug 11
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Key Insights The projected fair value for Medacta Group is CHF113 based on 2 Stage Free Cash Flow to Equity Medacta...Analyseartikel • Jul 27
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...Analyseartikel • Jul 03
Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analyseartikel • Apr 28
At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it led the SWX gainers with a relatively large...Analyseartikel • Apr 08
Is Medacta Group (VTX:MOVE) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Dec 25
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it received a lot of attention from a...Analyseartikel • Dec 09
Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Analyseartikel • Nov 09
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Sep 16
Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
While Medacta Group SA ( VTX:MOVE ) might not be the most widely known stock at the moment, it received a lot of...Aktionärsrenditen
| MOVE | CH Medical Equipment | CH Markt | |
|---|---|---|---|
| 7D | -2.3% | -1.2% | 2.5% |
| 1Y | 0% | -18.4% | 11.0% |
Rendite im Vergleich zur Industrie: MOVE übertraf die Branche Swiss Medical Equipment , die im vergangenen Jahr eine Rendite von -18.4 erzielte.
Rendite vs. Markt: MOVE hinter dem Markt Swiss zurück, der im vergangenen Jahr eine Rendite von 11 erzielte.
Preisvolatilität
| MOVE volatility | |
|---|---|
| MOVE Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 4.3% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.3% |
| 10% least volatile stocks in CH Market | 2.4% |
Stabiler Aktienkurs: MOVE hatte in den letzten 3 Monaten im Vergleich zum Swiss -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: MOVEDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1958 | 2,036 | Francesco Siccardi | www.medacta.com |
Medacta Group SA entwickelt, produziert und vertreibt orthopädische und neurochirurgische Medizinprodukte in Lateinamerika, Nordamerika, im asiatisch-pazifischen Raum sowie im Nahen Osten und Afrika. Das Unternehmen bietet personalisierte 3D-Planungstools für den Einsatz in der Hüft-, Knie-, Schulter-, Gelenkersatz-, Sportmedizin- und Wirbelsäulenchirurgie. Das Unternehmen wurde 1958 gegründet und hat seinen Hauptsitz in Castel San Pietro, Schweiz.
Medacta Group SA's Grundlagenzusammenfassung
| MOVE grundlegende Statistiken | |
|---|---|
| Marktanteil | CHF 2.66b |
| Gewinn(TTM) | CHF 88.01m |
| Umsatz(TTM) | CHF 630.46m |
30.4x
Kurs-Gewinn-Verhältnis 4.2x
Kurs-Umsatz-VerhältnisIst MOVE zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| MOVE Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | €683.83m |
| Kosten der Einnahmen | €225.17m |
| Bruttogewinn | €458.66m |
| Sonstige Ausgaben | €363.20m |
| Gewinn | €95.46m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
Sep 09, 2026
| Gewinn per Aktie (EPS) | 4.79 |
| Bruttomarge | 67.07% |
| Nettogewinnspanne | 13.96% |
| Schulden/Eigenkapital-Verhältnis | 44.9% |
Wie hat sich MOVE auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.8%
Aktuelle Dividendenrendite25%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/16 18:24 |
| Aktienkurs zum Tagesende | 2026/06/16 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Medacta Group SA wird von 12 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Samuel England | Berenberg |
| David Adlington | J.P. Morgan |
| Ilya Burgansky | Research Partners AG |